A Phase 2 interventional study of Acoramidis in Amyloid Cardiomyopathy, sponsored by Eidos Therapeutics, a BridgeBio company. Terminated at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Eidos Therapeutics, a BridgeBio company (part of BridgeBio) · Phase 2, Interventional, and Treatment
Study ended by the sponsor due to meeting Study Objectives
Masri A, Aras M, Grogan M, Jacoby D, Maurer MS, Shah SJ, Witteles R, Wong PW, Ji AX, DU J, Siddhanti S, Katz L, Sinha U, Fox JC, Judge DP. Acoramidis for Trans…PubMed 40216220 ↗. 1 publication citing this study linked from PubMed
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Amyloid Neuropathies, Familial with a site in United States — 23 open to participants now, 26 under way, 4 of them phase 3. Amyloid Neuropathies, Familial · United States.
Among the 58 studies in Amyloid Neuropathies, Familial with a site in United States, this one is the 23rd largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2018, is one of 2 in phase 2, and was the 18th registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →23 of the 58 studies in Amyloid Neuropathies, Familial with a site in United States are open now. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 30–80
University of Minnesota · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 17 · Phase 4 6
First in 2006; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 54 across 90 interventional studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 53 across the 38 interventional studies, 125 across the 20 observational. Of the 29 that completed or were terminated, 17 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 58 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eidos Therapeutics, a BridgeBio company, one of the names counted as BridgeBio. Under that name alone:
Eidos Therapeutics, a BridgeBio company is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
BridgeBio has 9 studies filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
11 of the studies in Amyloid Neuropathies, Familial with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05619302Phase 3Brigham and Women's HospitalMolecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis | 2026-12-31 |
| NCT07560306Phase 3Brigham and Women's Hospital[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy | 2027-03-30 |
| NCT07196839University of Texas Southwestern Medical CenterDetermining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study | 2026-12 |
| NCT07583823University of MinnesotaElevated Rate Pacing of Cardiac Amyloidosis | 2026-12-04 |
| NCT07062848Yale UniversityAn Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems. | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 58 studies in Amyloid Neuropathies, Familial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of acoramidis administered on a background of stable heart failure therapy.
An Open-Label Extension and Safety Monitoring Study of Patients with Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201
The primary objective of this study is to evaluate the long-term safety and tolerability of acoramidis administered to adult patients with symptomatic transthyretin amyloid cardiomyopathy (ATTR-CM) in patients who have completed the study AG10-201.
This study will be an Open-Label Extension and Safety Monitoring Study of up to 55 male and/or female patients with symptomatic ATTR-CM, ≥18 years of age, who have completed the Phase II Study AG10-201. Enrollment into the study will be followed by visits at Day 14, Day 45, 3 Months and every 3 months thereafter until Month 54. After the Month 54 Visit, clinic visits will be every 6 months. There will be one follow-up visit approximately 30 days after last dose.
If all doses are well tolerated, the duration of each patient's participation in the study will continue based on periodic recommendations of the acoramidis Data Monitoring Committee (DMC) and/or registration of the product for the treatment of symptomatic ATTR-CM.
The secondary objectives of this study are to characterize the pharmacokinetics (PK) of acoramidis administered orally twice daily in patients with symptomatic ATTR-CM, and to describe the long-term pharmacodynamic (PD) properties of acoramidis as assessed by established assays of transthyretin (TTR) stabilization, including Fluorescent Probe Exclusion (FPE) assay and Western blot, and to describe the PK-PD relationship of acoramidis in adult patients with symptomatic ATTR-CM.
The criteria were revised on the registry on Oct 14, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received open-label acoramidis 800 mg orally twice daily.
Drug: Acoramidis
Acoramidis 800 mg twice daily, oral administration
Also known as: AG10
Overall Summary of Treatment-Emergent Adverse Events.
Safety and tolerability were assessed by treatment-emergent adverse events (TEAEs), serious TEAEs, adverse events leading to treatment discontinuation.
Time frame: From the first dose of study drug until 30 days after the last dose of study drug. (Maximum exposure reported 84.1 months).
Acoramidis Pharmacodynamic Assessments of TTR Stabilization by Fluorescent Probe Exclusion Assay
Acoramidis binding to and/or stabilization of TTR will be evaluated by established ex vivo assays: Fluorescent Probe Exclusion (FPE) Assay
Time frame: Day 45 and Month 78
Acoramidis Pharmacodynamic Assessments: Prealbumin
Acoramidis binding to and/or stabilization of TTR will be evaluated by established ex vivo assays: quantitation of prealbumin (TTR).
Time frame: Baseline, Day 45, and Month 78
Plasma Concentrations of Acoramidis
Predose plasma concentrations of acoramidis were summarized by study visit in the PK Analysis Set.
Time frame: Baseline, Day 45, and Month 78
Plasma Concentrations of Acoramidis Acylglucuronide
Predose plasma concentrations of acoramidis acylglucuronide were summarized by study visit in the PK Analysis Set.
Time frame: Baseline, Day 45, and Month 78
| Milestone | Acoramidis HCl |
|---|---|
| Started | 47 |
| Completed | 0 |
| Not completed | 47 |
| Withdrew: Adverse event | 7 |
| Withdrew: Death | 12 |
| Withdrew: Physician decision | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Discontinued from study due to sponsor decision to end the study | 17 |
| Withdrew: Other study discontinuation reasons | 6 |
| Withdrew: Discordant entry noted after early site closure | 1 |
Safety and tolerability were assessed by treatment-emergent adverse events (TEAEs), serious TEAEs, adverse events leading to treatment discontinuation.
| Participants | Acoramidis HCl |
|---|---|
| Any TEAEs | 47 |
| Any Treatment-Related TEAEs | 7 |
| Any TEAEs with an Outcome of Death | 17 |
| Any Serious TEAEs | 40 |
| Any Treatment-Related Serious TEAEs | 1 |
| Any Non-Serious TEAEs | 46 |
| Any TEAEs Leading to Discontinuation of IMP | 6 |
| Any TEAEs Leading to Study Discontinuation | 17 |
Acoramidis binding to and/or stabilization of TTR will be evaluated by established ex vivo assays: Fluorescent Probe Exclusion (FPE) Assay
| Percent Target Engagement | Acoramidis HCl |
|---|---|
| Day 45 | 118.69 ± 90.707 |
| Month 78 | 103.54 ± 16.712 |
Acoramidis binding to and/or stabilization of TTR will be evaluated by established ex vivo assays: quantitation of prealbumin (TTR).
| mg/dL | Acoramidis HCl |
|---|---|
| Baseline (Day 1) | 21.55 ± 5.667 |
| Day 45 | 30.35 ± 5.028 |
| Month 78 | 30.68 ± 5.358 |
Predose plasma concentrations of acoramidis were summarized by study visit in the PK Analysis Set.
| ng/mL | Acoramidis HCl |
|---|---|
| Baseline (Predose) | 0.00 ± 0.000 |
| Day 45 (Predose) | 2166.13 ± 609.524 |
| Month 78 (Predose) | 2739.23 ± 870.981 |
Predose plasma concentrations of acoramidis acylglucuronide were summarized by study visit in the PK Analysis Set.
| ng/mL | Acoramidis HCl |
|---|---|
| Baseline (Predose) | 0.000 ± 0.0000 |
| Day 45 (Predose) | 2445.844 ± 2128.5501 |
| Month 78 (Predose) | 2911.385 ± 2275.2234 |
Collected over From the first dose of study drug until 30 days after the last dose of study drug. (Maximum exposure reported 84.1 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acoramidis HCl | 17/47 (36.2%) | 40/47 (85.1%) | 46/47 (97.9%) |
| Event | Acoramidis HCl |
|---|---|
| Cardiac failure acuteCardiac disorders | 14/47 |
| Acute kidney injuryRenal and urinary disorders | 12/47 |
| FallInjury, poisoning and procedural complications | 8/47 |
| Atrial fibrillationCardiac disorders | 6/47 |
| Cardiac failure congestiveCardiac disorders | 6/47 |
| Cardiorenal syndromeCardiac disorders | 6/47 |
| Atrial flutterCardiac disorders | 5/47 |
| Cardiac failureCardiac disorders | 5/47 |
| Cardiac amyloidosisCardiac disorders | 4/47 |
| Cardiogenic shockCardiac disorders | 4/47 |
| Event | Acoramidis HCl |
|---|---|
| FallInjury, poisoning and procedural complications | 25/47 |
| ConstipationGastrointestinal disorders | 16/47 |
| Back painMusculoskeletal and connective tissue disorders | 15/47 |
| COVID-19Infections and infestations | 13/47 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/47 |
| FatigueGeneral disorders | 12/47 |
| CoughRespiratory, thoracic and mediastinal disorders | 12/47 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/47 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 11/47 |
| HypervolaemiaMetabolism and nutrition disorders | 11/47 |
| Age, Categorical(Participants) | Acoramidis HCl |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 2 |
| >=65 years | 45 |
| Age, Continuous(Years) | Acoramidis HCl |
|---|---|
| Mean | 74.3 ± 6.76 |
| Sex: Female, Male(Participants) | Acoramidis HCl |
|---|---|
| Female | 4 |
| Male | 43 |
| Race (NIH/OMB)(Participants) | Acoramidis HCl |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 9 |
| White | 35 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Ethnicity (NIH/OMB)(Participants) | Acoramidis HCl |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 42 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(Participants) | Acoramidis HCl |
|---|---|
| United States | 47 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Sep 2025, 85 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Jul 2027 → Sep 2025 and completion Jul 2027 → Sep 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Study ended by the sponsor due to meeting Study Objectives
Masri A, Aras M, Grogan M, Jacoby D, Maurer MS, Shah SJ, Witteles R, Wong PW, Ji AX, DU J, Siddhanti S, Katz L, Sinha U, Fox JC, Judge DP. Acoramidis for Trans…PubMed 40216220 ↗. 1 publication citing this study linked from PubMed
Study ended by the sponsor due to meeting Study Objectives
Masri A, Aras M, Grogan M, Jacoby D, Maurer MS, Shah SJ, Witteles R, Wong PW, Ji AX, DU J, Siddhanti S, Katz L, Sinha U, Fox JC, Judge DP. Acoramidis for Trans…PubMed 40216220 ↗. 1 publication citing this study linked from PubMed
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acoramidis
Amyloid Neuropathies, Familial →
Eidos Therapeutics, a BridgeBio company →